Cue Biopharma, Inc. (CUE) NASDAQ

0.72

-0.0035(-0.49%)

Updated at October 03 03:02PM

Currency In USD

Cue Biopharma, Inc.

Address

21 Erie Street

Boston, MA 02139

United States of America

Phone

617 949 2680

Sector

Healthcare

Industry

Biotechnology

Employees

41

First IPO Date

January 02, 2018

Key Executives

NameTitlePayYear Born
Mr. Daniel R. Passeri J.D., M.Sc.Chief Executive Officer & Director682,7261961
Dr. Rodolfo J. Chaparro Ph.D.Co-Founder316,6281973
Dr. Ronald D. Seidel III, Ph.D.Co-Founder316,6281976
Mr. Colin G. Sandercock J.D., MSESenior Vice President, General Counsel & Secretary381,4241957
Ms. Kerri-Ann Millar CPAChief Financial Officer577,2761970
Dr. Matteo Levisetti M.D.Chief Medical Officer595,3491969
Ms. Lucinda WarrenChief Business Officer01969
Dr. Steven C. Almo Ph.D.Co-Founder and Chairman of Scientific & Clinical Advisory Board01961
Dr. Daniel G. Baker M.D., Ph.D.Interim Chief Development Officer01950

Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.